Literature DB >> 12927929

Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens.

Yasuhiro Asahina1, Namiki Izumi, Masakatsu Uchihara, Osamu Noguchi, Yuki Nishimura, Kazunari Inoue, Ken Ueda, Kaoru Tsuchiya, Kosei Hamano, Jun Itakura, Shozo Miyake.   

Abstract

BACKGROUND/AIMS: To address the molecular mechanism for enhanced antiviral efficacy associated with a frequent dosing of interferon (IFN)-beta.
METHODS: Serum hepatitis C viral (HCV) dynamics, double-stranded RNA-activated protein kinase (PKR) mRNA and MxA mRNA levels in peripheral blood mononuclear cells (PBMC) were analyzed serially in 140 patients who were randomly assigned to a twice daily (3 MU bid) or once daily (6 MU qd) administration group.
RESULTS: In twice daily group, the rate of HCV decline during the second phase was 2-fold greater than in the once daily group (P=0.04). Peak PKR and MxA gene expression levels in the first phase (observed 4 h after a single administration) were 2-fold higher in the once daily group. However, the expression in the second phase was maintained at a significantly higher level in the twice daily group. Initial and peak expression levels were related to initial viral load. Basal expressions in PBMC were significantly correlated with those in the liver tissue (PKR, r=0.81; MxA, r=0.75, respectively, P<0.0001).
CONCLUSIONS: Our data suggest that elimination of HCV-infected cells is enhanced by twice daily dosing of IFN-beta, and that this enhanced effect is associated with a higher intracellular expression of PKR and MxA during the second phase.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12927929     DOI: 10.1016/s0168-8278(03)00287-3

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C.

Authors:  Hiroaki Okushin; Kazuhiko Morii; Koichi Uesaka; Shiro Yuasa
Journal:  World J Hepatol       Date:  2010-06-27

Review 2.  Is interferon-beta an alternative treatment for chronic hepatitis C?

Authors:  Ricardo Moreno-Otero; María Trapero-Marugán; Elena Gómez-Domínguez; Luisa García-Buey; José A Moreno-Monteagudo
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

3.  Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.

Authors:  Catherine O'Doherty; Alexander Favorov; Shirley Heggarty; Colin Graham; Olga Favorova; Michael Ochs; Stanley Hawkins; Michael Hutchinson; Killian O'Rourke; Koen Vandenbroeck
Journal:  Pharmacogenomics       Date:  2009-07       Impact factor: 2.533

4.  Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling.

Authors:  Dirk Holzinger; Carl Jorns; Silke Stertz; Stéphanie Boisson-Dupuis; Robert Thimme; Manfred Weidmann; Jean-Laurent Casanova; Otto Haller; Georg Kochs
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

5.  Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.

Authors:  Jordan J Feld; Santosh Nanda; Ying Huang; Weiping Chen; Maggie Cam; Susan N Pusek; Lisa M Schweigler; Dickens Theodore; Steven L Zacks; T Jake Liang; Michael W Fried
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

6.  The impact of host factors on management of hepatitis C virus.

Authors:  Mahmoud Aboelneen Khattab; Mohammed Eslam
Journal:  Hepat Mon       Date:  2012-04-30       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.